Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sutro BiopharmaSTRO -4.16%45 Cash-to-Debt is 15.24 as of Jun. 2026, which is 46% above its 10-year median of 10.42. GuruFocus rates STRO with a GF Score™ of 45/100 and a GF Value™ of $5.50 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,400 Biotechnology companies, Sutro Biopharma ranks better than 59% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sutro Biopharma's cash to debt ratio for the quarter that ended in Jun. 2026 was 15.24.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Sutro Biopharmacould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Sutro Biopharma's Cash-to-Debt or its related term are showing as below:
STRO'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.51 Med: 10.42 Max: No Debt
Current: 15.24
During the past 10 years, Sutro Biopharma's highest Cash to Debt Ratio was No Debt. The lowest was 1.51. And the median was 10.42.
STRO's Cash-to-Debt is ranked better than 59% of 1400
companies
in the Biotechnology industry
Industry Median: 6.57
vs STRO: 15.24
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Sutro Biopharma Cash-to-Debt Related Terms
Sutro Biopharma Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Sutro Biopharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Sutro Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (STRO) has a Cash-to-Debt of 15.24 as of Jun. 2026. This is 46% above median its historical median of 10.42. Over the past decade, Sutro Biopharma's Cash-to-Debt has ranged from 1.51 to 10,000.00. According to the industry distribution chart, Sutro Biopharma ranks #574 out of 1400 companies in the Biotechnology industry, placing it in the top 41%.
Is Sutro Biopharma's Cash-to-Debt too high?
Sutro Biopharma's current Cash-to-Debt of 15.24 is 46% above median its 10-year median of 10.42. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.57. Sutro Biopharma's value of 15.24 is 132% above this industry median. Based on the distribution chart, Sutro Biopharma ranks #574 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sutro Biopharma has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Cash-to-Debt compare to AVIR and IPSC?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #574 out of 1400 companies for Cash-to-Debt. This puts Sutro Biopharma in the upper half of its industry. The industry median Cash-to-Debt is 6.57. Sutro Biopharma's value of 15.24 is 132% above this benchmark. Historically, Sutro Biopharma's own Cash-to-Debt has ranged from 1.51 to 10,000.00 over the past decade. While the company's 10-year median is 10.42 vs. the industry median of 6.57, Sutro Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.57, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sutro Biopharma's current Cash-to-Debt of 15.24 is 132% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sutro Biopharma's current Cash-to-Debt is 15.24, which is 46% above median its own 10-year median of 10.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (STRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.50, compared to a current price of $20.46 — trading 272% above its estimated fair value. The current Cash-to-Debt is 15.24, which is 46% above median its 10-year median of 10.42 and 132% above the Biotechnology industry median of 6.57. Sutro Biopharma's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Sutro Biopharma (STRO), the current Cash-to-Debt is 15.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (STRO) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of $20.46 is trading 272% above its estimated GF Value™ of $5.50.
GuruFocus considers Sutro Biopharma to be Significantly Overvalued.
Key valuation signals for STRO:
Cash-to-Debt: 15.24 (46% above median its 10-year median of 10.42)
GF Value™: $5.50 vs. price of $20.46 (272% above fair value)
Industry Position: 132% above the Biotechnology median (#574 of 1400)
No single metric tells the full story. See the STRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score
Get the complete analysis for STRO
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STRO has been successfully added to your 
